Table 1 hrHPV type-specific prevalence and cytological evaluation in cases and controls
Controls (NEG/CIN1) n = 237 | Cases (CIN2+) n = 79 | |||||
|---|---|---|---|---|---|---|
Number | Percent | Number | Percent | p value^ | OR (95% CI) | |
hrHPV positivity* | ||||||
HPV 16+ | 111 | 46.8 | 48 | 60.8 | 0.038 | 1.8 (1.05–2.94) |
HPV 33+ | 8 | 3.4 | 3 | 3.8 | 1.000 | 1.1 (0.32–4.04) |
HPV 31+ | 28 | 11.8 | 10 | 12.7 | 0.843 | 1.1 (0.51–2.31) |
HPV 18+ | 47 | 19.8 | 1 | 1.3 | 0.000 | 0.1 (0.0–0.30) |
Other hrHPV+** | 43 | 18.1 | 17 | 21.5 | 0.511 | 1.0 (0.60–1.67) |
Cytological evaluation | ||||||
Normal | 148 | 62.5 | 34 | 43.0 | 0.004 | 0.5 (0.27–0.76) |
ASCUS+ | 89 | 38.0 | 45 | 57.0 | 0.004 | 2.2 (1.32–3.68) |
LSIL+ | 74 | 31.2 | 41 | 51.9 | 0.001 | 2.4 (1.42–3.99) |
HSIL+ | 10 | 4.2 | 22 | 27.9 | 0.000 | 8.8 (3.98–19.3) |
HPV and cytology | ||||||
HPV16/18+ and ASCUS+a | 24 | 10.3 | 16 | 20.3 | 0.030 | 2.3 (1.14–4.47) |
HPV16/18+ and LSIL+b | 17 | 7.2 | 14 | 17.7 | 0.014 | 2.8 (1.32–5.89) |
HPV16/18+ and HSIL+c | 5 | 2.1 | 5 | 6.3 | 0.128 | 3.1 (0.94–10.4) |
HPV16/18+ and normald | 148 | 62.5 | 34 | 43.0 | 0.004 | 0.5 (0.27–0.76) |
HPV16/18− and ASCUS+e | 65 | 27.4 | 29 | 36.7 | 0.121 | 1.5 (0.90–2.62) |